Davis v. Dow Corning Corp.

530 N.W.2d 178, 209 Mich. App. 287
CourtMichigan Court of Appeals
DecidedMarch 7, 1995
DocketDocket 165650
StatusPublished
Cited by1 cases

This text of 530 N.W.2d 178 (Davis v. Dow Corning Corp.) is published on Counsel Stack Legal Research, covering Michigan Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Davis v. Dow Corning Corp., 530 N.W.2d 178, 209 Mich. App. 287 (Mich. Ct. App. 1995).

Opinion

Per Curiam.

Plaintiffs appeal by leave granted from a protective order entered by the circuit court concerning ex parte discovery interviews with plaintiffs’ treating physicians in this silicone gel breast implant products liability litigation. We affirm.

All silicone gel implant products liability actions pending in this state have been consolidated for purposes of pretrial discovery pursuant to Administrative Order No. 1993-2, 442 Mich cix (1993).

On March 19, 1993, defendant implant manufacturers moved for an order permitting them to conduct ex parte interviews with plaintiffs’ treating physicians. After hearing oral argument on May 7, 1993, the court ruled that defendants were entitled to interview the physicians, but allowed the parties to file additional briefs to address whether plaintiffs could contact the physicians to inform them that they had the right to decline any ex parte meetings. The court indicated that it would issue its ruling on May 21, 1993. Before that date, however, plaintiffs’ counsel sent an open letter to the treating physicians requesting them not to speak with defense counsel unless plaintiffs’ counsel was also present. That letter read as follows:

One or more attorneys representing breast implant manufacturer DOW [sic] Corning (or possibly *290 other breast implant manufacturers) may attempt to contact you to arrange a meeting and discussion concerning your patient(s) who has received breast implants. I respectfully request that you choose not to speak with these attorneys unless I am present. I am the attorney representing the female recipients of breast implants.
There is no law that says you must speak with the defense attorneys. The defense attorneys may try to set up a private meeting because it has been their historical practice to try to use a patient’s treating physician to dispute the medical claim— to place blame on anything other than their product.
As you are aware, the problems with breast implants are only now beginning to filter down to physician practitioners. The medical dangers of silicone and gel implants are being increasingly reported in the professional and lay press.
From the evidence developed to date, it is apparent that the silicone breast implant manufacturers misled America’s physicians both about the safety and dangers of breast implants. They are continuing in their efforts in spite of the pda ban on gel implants for nonclinical study reconstructive surgery and in spite of the pending investigation into the health effects of all implants with silicone envelopes. Indeed, at least two plastic surgeons have filed fraud actions against the gel implant manufacturers. . . .
The Charfoos & Christensen law firm has not sued any of the physician implanters or other health care providers involved with problem [sic]. It is our belief that both physicians and patients were misled by the implant manufacturers.
You do not have to talk with the manufacturer attorneys unless you wish to. If you want to meet with the attorneys for the breast implant manufacturers, please ask that I be included in the meeting as I am the attorney representing your patient.
*291 Thank you for your help. Of course, please call if you have any questions.

Plaintiffs’ counsel also referred to the mass mailing letter in an interview that was published in the Detroit Legal News. In response to those actions, defendants on May 20, 1993, filed an emergency motion for a protective order.

At the May 21 hearing, the court issued its ruling with respect to the March 19 motion. It ruled that both plaintiffs’ and defendants’ representatives were permitted to conduct ex parte interviews with plaintiffs’ treating physicians, provided that they specifically advised the physicians that they were free to grant or decline an ex parte interview. That ruling was incorporated into the court’s June 1, 1993, order.

On June 2, 1993, the court ruled from the bench that it was improper for plaintiffs’ counsel to request the physicians to decline interviews by defense counsel in the absence of counsel for their patients. In a written order dated June 10, 1993, the court granted defendants’ May 20 motion for a protective order, requiring plaintiffs’ counsel to send a court-drafted letter on the law firm’s letterhead to the treating physicians informing them that they were not required to request that plaintiffs’ counsel participate in the ex parte meetings and to publish the letter in the Detroit Legal News. That letter was to read as follows:

On May 12, 1993, I issued an open letter to Michigan physicians in the form of a press release. I also wrote to you on May 13, 1993 concerning pending breast implant litigation. Subsequently, the Wayne County Circuit Court, where all Michigan state court breast implant cases are pending, has entered an order, a copy of which is enclosed. As you will note, this order provides that defense *292 attorneys are permitted to speak with physicians concerning any claim arising out of the silicone implant case filed by a patient who has signed a medical authorization for release of information. The Court has also ruled that such patients and their attorneys may not request the physician to speak with a defense attorney only if the patient’s attorney is also permitted to be present.
Any request from my office contained in any prior communication to you, to the effect that you should choose not to speak to a breast implant manufacturer’s attorney unless I am present, is hereby withdrawn, pursuant to the foregoing orders of the court.

Plaintiffs now appeal by leave granted from the June 10 order. The American Civil Liberties Union has filed, by leave granted, a brief amicus curiae, that addresses the First Amendment issue.

On appeal, plaintiffs first argue that the trial court erred in relying on Domako v Rowe, 438 Mich 347; 475 NW2d 30 (1991), to support its ruling that defendants’ attorneys were entitled to communicate ex parte with plaintiffs’ treating physicians. 1 Plaintiffs assert that the holding of that medical malpractice case is inapposite in the context of products liability litigation.

In Domako, our Supreme Court held that the defense counsel properly could conduct an ex parte interview with the plaintiff’s treating physician once the physician-patient privilege had been waived. The Court noted that under MCL 600.2157; MSA 27A.2157, the physician-patient privilege is waived when a patient brings a malpractice or personal injury suit. Id. at 353-354. *293 Likewise, under MCR 2.314(A)(1)(b), medical information is subject to discovery when the mental or physical condition of a party is in controversy. Id. at 354.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
530 N.W.2d 178, 209 Mich. App. 287, Counsel Stack Legal Research, https://law.counselstack.com/opinion/davis-v-dow-corning-corp-michctapp-1995.